Tiziana Life Sciences (TLSA) announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal foralumab in various neurodegenerative diseases including Multiple Sclerosis, MS, Alzheimer’s disease, ALS, and Parkinsons disease. Tiziana’s CEO, Ivor Elrifi, added, “We are encouraged by the insights presented in this article, which underscore the potential of Foralumab as a groundbreaking therapy for neurodegenerative diseases. At Tiziana, we are committed to advancing innovative treatments that address significant unmet medical needs, and this publication reinforces our dedication to improving patient outcomes in progressive MS and other neurological diseases.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Advances Alzheimer’s Treatment with Intranasal Foralumab
- Tiziana Life Sciences announces first patient dosed with intranasal foralumab
- Tiziana Life Sciences Expands MS Clinical Trial Network
- Tiziana Life Sciences expands Phase 2 trial for non-active SPMS
- Tiziana Life Sciences Secures ALS Trial Funding